文献速递血栓与止血

肿瘤性肝脏手术中延长药物性血栓预防安全有效

Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective.
PubMed 文献 · J Thromb Haemost · 2017-09-27

该研究纳入2013年8月至2015年4月因恶性肿瘤行肝切除的124例患者,实施延长药物性血栓预防方案。出院后114例(91.9%)继续使用依诺肝素至小范围/微创肝切除后14天或大范围肝切除/有VTE史者28天。90天随访内无术后症状性深静脉血栓或肺栓塞事件,2例(1.6%)轻微出血停药后缓解,无90天死亡。

要点

  • 124例恶性肿瘤肝切除患者接受延长药物性血栓预防,90天内无VTE事件。
  • 112例(90.3%)标准方案CT未见肺栓塞或其他胸、内脏或髂股静脉血栓。
  • 2例(1.6%)轻微出血停用依诺肝素后缓解,无需输血或再手术。

核心结论

  • 这些初步数据提示,对肝脏手术患者延长药物性血栓预防是安全有效的。

研究设计与样本

  • 研究纳入2013年8月至2015年4月因恶性肿瘤行肝切除的124例患者,实施延长药物性血栓预防方案。

主要发现

  • 队列包括39例(31.2%)大范围肝切除和38例(31.5%)小范围/微创入路。
  • 术中、术后和总体输血率分别为5.6%、8.1%和10.5%。
  • 药物性血栓预防在术后第0天开始于40例(32.3%)患者,在术后第1天开始于84例(67.7%)患者。
  • 90天随访期间,未诊断术后症状性深静脉血栓或肺栓塞事件。
  • 112例(90.3%)研究患者的标准方案胸部、腹部和盆腔CT扫描显示无肺栓塞或其他胸部、内脏或髂股静脉血栓。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials The risk for venous thromboembolism after liver surgery remains high in the modern era. We evaluated the safety/efficacy of extended anticoagulation in liver surgery. This protocol reports zero venous thromboembolism events in 124 liver surgery patients. Extended anticoagulation after oncologic liver surgery is safe and effective. SUMMARY: Background The incidence of venous thromboembolism (VTE) after liver surgery remains high. Objective To evaluate the safety and efficacy of extended pharmacologic thromboprophylaxis after liver surgery for the prevention of VTE. Patient/Methods From August 2013 to April 2015, 124 patients who underwent liver resection for malignancy were placed on an extended pharmacologic thromboprophylaxis protocol. Intraoperative VTE prophylaxis included thromboembolic deterrent hoses and sequential compression devices. Once hemostasis had been ensured following hepatectomy, daily anticoagulant VTE prophylaxis was initiated for the duration of hospitalization. After hospital discharge, the large majority of patients (114, 91.9%) continued to receive anticoagulant thromboprophylaxis (enoxaparin) to complete a total course of 14 days after minor/minimally invasive hepatectomy or 28 days after major hepatectomy or a history of VTE. Results The cohort included 39 (31.2%) major hepatectomies and 38 (31.5%) minor/minimally invasive approaches. The intraoperative, postoperative and overall transfusion rates were 5.6%, 8.1%, and 10.5%, respectively. Pharmacologic thromboprophylaxis was started on postoperative day (POD) 0 for 40 (32.3%) patients and on POD 1 for 84 (67.7%) patients. During 90 days of follow-up, no postoperative symptomatic deep vein thrombosis or pulmonary embolic events were diagnosed. Standard-protocol computed tomography scans of the chest, abdomen and pelvis that were obtained for 112 (90.3%) study patients showed no pulmonary emboli, or other thoracic, splanchnic or ileofemoral vein thromboses. Two (1.6%) patients had minor bleeding events that resolved after discontinuation of enoxaparin, requiring neither blood transfusion nor reoperation. The severe complication rate was 5.6%, with no 90-day mortalities. Conclusions These preliminary data suggest that extended pharmacologic thromboprophylaxis for liver surgery patients is safe and effective.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kim BJ, Day RW, Davis CH, et al. Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. J Thromb Haemost. 2017. PMID: 28846822. doi:10.1111/jth.13814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。